Coloplast Reports Q3 2025/26 Results: Solid Performance Amid Market Headwinds
Coloplast, a leading provider of continence and wound‑care solutions, announced its third‑quarter results for the 2025/26 financial year on 18 August 2026. The company’s performance largely aligned with market expectations, underscoring the resilience of its core business units while highlighting the challenges posed by reimbursement reforms and currency fluctuations.
Revenue and Core Growth
Revenue increased by approximately 6 % year‑on‑year, driven by organic growth of roughly the same magnitude across the company’s main segments. This growth reflects robust demand for continence and chronic‑care products, particularly in the United States and Europe outside China. The company’s ability to maintain organic expansion while navigating foreign‑exchange headwinds reinforces its competitive positioning.
Earnings and Operating Margin
Earnings before tax and adjusted operating profit both rose, though operating margin slipped marginally compared with the prior year. The decline is attributed to:
- Currency effects: Weakening of the euro and other key currencies eroded profit contributions in non‑US markets.
- Non‑recurring impairment: A modest hit related to the Kerecis unit reduced earnings, but the impact was isolated and is expected to be a one‑off event.
Despite the margin compression, the company’s EBITDA margin remained near historical levels, indicating operational discipline.
Segment‑Level Performance
| Segment | Revenue Trend | EBIT Margin | Comments |
|---|---|---|---|
| Continence Care | +7 % | +5 % | Strong demand in North America; new product launches |
| Interventional Urology | +8 % | +4 % | Expanding procedural market; higher margin profile |
| Biologics | –4 % | –3 % | Reimbursement rule changes reduced net sales and margins |
| Wound & Tissue Repair | +3 % | +2 % | Modest gains, stable demand cycle |
| Ostomy Care | +5 % | +4 % | Steady growth, particularly in the US and EU |
The decline in the Biologics segment underscores the sensitivity of reimbursement‑driven revenue streams to policy changes. Coloplast’s response strategy involves diversifying product portfolios and engaging with payers to mitigate such risks.
Net Profit and Shareholder Returns
Net profit surged by more than 80 % year‑on‑year, largely driven by favorable foreign‑exchange gains and a lower financial‑cost profile. Adjusted earnings per share (EPS) mirrored this improvement, supporting the firm’s continued guidance for the fiscal year.
Management highlighted a new capital‑allocation and resource‑allocation strategy designed to:
- Prioritize the United States market, where reimbursement reforms are underway.
- Sustain leadership within the Chronic Care portfolio through targeted R&D investment.
- Maintain operational discipline to manage cost pressures without compromising quality outcomes.
Coloplast also announced a shareholder‑return program, including a new share‑repurchase plan, reinforcing confidence in its cash‑flow generation and long‑term value creation.
Outlook and Market Reception
The company reiterated guidance for 2025/26, forecasting 5–6 % organic revenue growth and a comparable level of EBIT expansion in constant currencies. This outlook is viewed by investors as realistic given current market dynamics and Coloplast’s strategic focus areas.
Analysts note that while reimbursement reforms pose a risk to segments such as Biologics, the company’s diversified portfolio and strong market presence in high‑margin sectors buffer against short‑term volatility. The continued investment in innovation, coupled with disciplined cost management, positions Coloplast to maintain its industry leadership and deliver quality outcomes for patients while balancing cost considerations.
Overall, Coloplast’s third‑quarter results demonstrate stability and strategic clarity, suggesting that the company is well‑positioned to navigate prevailing market headwinds while pursuing sustainable growth.
